0001209191-23-048254.txt : 20230905 0001209191-23-048254.hdr.sgml : 20230905 20230905200441 ACCESSION NUMBER: 0001209191-23-048254 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shawver Laura CENTRAL INDEX KEY: 0001551891 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39756 FILM NUMBER: 231237518 MAIL ADDRESS: STREET 1: 1255 CRESCENT GREEN DRIVE, SUITE 250 CITY: CARY STATE: NC ZIP: 27518 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001671858 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811489190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL, SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-771-9307 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL, SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Silverback Therapeutics, Inc. DATE OF NAME CHANGE: 20160412 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-01 0 0001671858 ARS Pharmaceuticals, Inc. SPRY 0001551891 Shawver Laura C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 1 0 0 0 1 Common Stock 2023-09-01 4 M 0 2997 1.27 A 213343 D Common Stock 2023-09-01 4 M 0 97003 1.27 A 310346 D Common Stock 2023-09-01 4 S 0 100000 7.7052 D 210346 D Stock Option (Right to Buy) 1.27 2023-09-01 4 M 0 2997 0.00 D 2030-04-28 Common Stock 2997 0 D Stock Option (Right to Buy) 1.27 2023-09-01 4 M 0 97003 0.00 D 2030-04-28 Common Stock 97003 55235 D The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.24 to $8.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Immediately exercisable. /s/ Kathleen Scott, Attorney-in-Fact 2023-09-05